Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a
very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding …

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) arise from neuroendocrine
cells found throughout the gastrointestinal tract and islet cells of the pancreas. The incidence …

Continuous progress in the diagnostics and treatment of neuroendocrine neoplasms
(NENs), the emerging results of new clinical trials, and the new guidelines issued by medical …

Background Retrospective studies and single center experiences suggest a role of
capecitabine combined with temozolomide (CAPTEM) in neuroendocrine tumors (NENs) …

Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms, arising from cells
of the endocrine system, with various clinical behaviors. Although these neoplasms are …

Background. Neuroendocrine tumors (NETs) are characterized by having behavior and
prognosis that depend upon tumor histology, primary site, staging, and proliferative index …

Introduction One of the concepts of theranostics in nuclear medicine is peptide receptor
radionuclide therapy (PRRT), whereby labeled somatostatin analogs are used for imaging …

Background: Capecitabine and temozolomide combination (CAPTEM) is associated with
high response rates in patients with advanced neuroendocrine neoplasms (NENs). We …

Background Peptide receptor radionuclide therapy (PRRT) is one of the most effective
therapeutic options for the treatment of metastatic, well-differentiated neuroendocrine tumors …

Introduction The peptide receptor radionuclide therapy (PRRT) with 90 Y and 177 Lu is a
form of molecular targeted therapy for inoperable or disseminated neuroendocrine tumors …